Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy
- 4 March 2014
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 22 (7) , 1959-1964
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomitingEuropean Journal of Pharmacology, 2012
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2011
- Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantationAnnals of Oncology, 2010
- A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapyAnnals of Oncology, 2009
- A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapyAnnals of Oncology, 2009
- Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trialThe Lancet Oncology, 2009
- Palonosetron (Aloxi®) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapySupportive Care in Cancer, 2008
- Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancerSupportive Care in Cancer, 2007
- Pharmacokinetic and Safety Evaluation of Palonosetron, a 5‐Hydroxytryptamine‐3 Receptor Antagonist, in U.S. and Japanese Healthy SubjectsThe Journal of Clinical Pharmacology, 2004
- Urinary 5-Hydroxyindoleacetic acid (5-HIAA) excretion during multiple-day high-dose chemotherapyEuropean Journal of Cancer, 1998